These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 4433667)

  • 1. Parameters of serum complement in relation to tumor therapy.
    Drake WP; Mardiney MR
    Biomedicine; 1974 May; 21(5):206-9. PubMed ID: 4433667
    [No Abstract]   [Full Text] [Related]  

  • 2. The measurement and manipulation of hemolytic complement levels in tumor bearing C57BL/6 mice.
    Drake WP; Ungaro PC; Mardiney MR
    Biomedicine; 1973 Jul; 18(4):284-9. PubMed ID: 4803701
    [No Abstract]   [Full Text] [Related]  

  • 3. The combined effect of drugs and tumor-specific antibodies in protection against a mouse lymphoma.
    Davies DA
    Cancer Res; 1974 Nov; 34(11):3040-3. PubMed ID: 4418406
    [No Abstract]   [Full Text] [Related]  

  • 4. Passive administration of antiserum and complement in producing anti-EL4 cytotoxic activity in the serum of C57BL-6 mice.
    Drake WP; Ungaro PC; Mardiney MR
    J Natl Cancer Inst; 1973 Apr; 50(4):909-14. PubMed ID: 4574188
    [No Abstract]   [Full Text] [Related]  

  • 5. Therapy with allogeneic immune peritoneal cells.
    Dullens HF; Den Otter W
    Cancer Res; 1974 Jul; 34(7):1726-30. PubMed ID: 4833917
    [No Abstract]   [Full Text] [Related]  

  • 6. Generation of non-complement-fixing, blocking factors by lysosomal extract treatment of cytotoxic anti-tumor antibodies.
    Dauphinee MJ; Talal N; Witz IP
    J Immunol; 1974 Sep; 113(3):948-53. PubMed ID: 4413555
    [No Abstract]   [Full Text] [Related]  

  • 7. Role of macrophages in tumour immunity. II. Involvement of a macrophage cytophilic factor during syngeneic tumour growth inhibition.
    Evans R; Alexander P
    Immunology; 1972 Oct; 23(4):627-36. PubMed ID: 4563478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Host reactivity against clonable tumor cells and the total tumor cell population, studied in a syngeneic murine lymphoma system.
    Gjedde SB
    Acta Pathol Microbiol Immunol Scand C; 1983 Apr; 91(2):101-8. PubMed ID: 6349250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of tumor and histocompatibility antigens in sera of lymphoma-bearing mice.
    Fujimoto S; Chen CH; Sabbadini E; Sehon AH
    J Immunol; 1973 Oct; 111(4):1093-100. PubMed ID: 4728678
    [No Abstract]   [Full Text] [Related]  

  • 10. Immunoprophylaxis and immunotherapy of EL4 lymphoma.
    Ghose T; Guclu A; Tai J; Mammen M; Norvell ST
    Eur J Cancer (1965); 1977 Sep; 13(9):925-35. PubMed ID: 913475
    [No Abstract]   [Full Text] [Related]  

  • 11. Lymphokine preparations: a new approach to cancer immunotherapy.
    Papermaster BW; Kaltenbach ML
    Mo Med; 1978 Dec; 75(12):607-9, 612. PubMed ID: 723839
    [No Abstract]   [Full Text] [Related]  

  • 12. Factors related to therapeutic efficacy in adoptive chemoimmunotherapy of a Friend virus-induced lymphoma.
    Fass L; Fefer A
    Cancer Res; 1972 Nov; 32(11):2427-31. PubMed ID: 5082591
    [No Abstract]   [Full Text] [Related]  

  • 13. [Modulating effect of immunotherapy with modified tumor cells in transplantable lymphoma].
    Bratus' GG; Darchuk GF; Komissarenko VG; Nastenko EP
    Eksp Onkol; 1987; 9(2):36-40. PubMed ID: 3582237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of various forms of therapy in two different mouse tumor systems.
    Dullens HF; Vennegoor C; De Weger RA; Woutersen F; Woutersen RA; Den Otter W
    Cancer Treat Rep; 1979 Jan; 63(1):99-109. PubMed ID: 421238
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment of a Moloney lymphoma with cyclophosphamide and H-2-incompatible spleen cells.
    Fefer A
    Cancer Res; 1973 Apr; 33(4):641-4. PubMed ID: 4696464
    [No Abstract]   [Full Text] [Related]  

  • 16. Antigenic modulation as a mechanism for tumor escape from immune destruction: identification of modulation-positive and modulation-negative mouse lymphomas with xenoantisera to murine leukemia virus gp70.
    Stackpole CW; Cremona P; Leonard C; Stremmel P
    J Immunol; 1980 Oct; 125(4):1715-23. PubMed ID: 6251136
    [No Abstract]   [Full Text] [Related]  

  • 17. The kinetics of the interaction of heterologous anti-tumor serum and heterologous complement in non-tumor bearing mice.
    Drake WP; Roberts GC; Pendergrast WJ; Mardiney MR
    Biomedicine; 1975 Nov; 22(6):502-8. PubMed ID: 1225381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural cytotoxic cells against solid tumors in mice. III. A comparison of effector cell antigenic phenotype and target cell recognition structures with those of NK cells.
    Lattime EC; Pecoraro GA; Stutman O
    J Immunol; 1981 May; 126(5):2011-4. PubMed ID: 7217680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Combined surgical and specific passive xenogenic immunotherapy in UVT tumor-bearing inbred XVII/Bln mice].
    Winzer KJ
    Z Exp Chir; 1981; 14(2):90-7. PubMed ID: 7257469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of an AKR lymphoma by antibody and chlorambucil.
    Ghose T; Guclu A; Tai J
    J Natl Cancer Inst; 1975 Dec; 55(6):1353-7. PubMed ID: 1107575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.